Katy Tsai

6PUBLICATIONS
78CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 05, 2026
A Technique for the Generation of Mucosal and Acral Melanoma Cell Lines.

|Jun 02, 2026
Study Protocol to Characterize Symptom Experience During Immune Checkpoint Inhibitor Therapy for Cutaneous Melanoma.

|Apr 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

|Oct 15, 2025
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.

Ling Zhu, Yee-Ming M Cheung, Cherie Chiang

|Jul 08, 2025
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).

Michael K Wong, Mohammed M Milhem, Joseph J Sacco

|Mar 05, 2025
Single-Cell Analyses Reveal a Functionally Heterogeneous Exhausted CD8+ T-cell Subpopulation That Is Correlated with Response to Checkpoint Therapy in Melanoma.

Kelly M Mahuron, Osmaan Shahid, Prachi Sao

Pageof 1

Frequent Collaborators

2 joint publications

Adil I Daud

1 joint publications

Kelly M Mahuron

1 joint publications

Osmaan Shahid

1 joint publications

Prachi Sao